Vertex's flagship TRIKAFTA is shrinking, and that is by design. TRIKAFTA/KAFTRIO revenue fell 2.1% to $2,497.2 million in the second quarter, but its successor ALYFTREK jumped 266% to $573.6 million, pushing the whole cystic fibrosis franchise up 10.6% to $3,207.9 million. The catch is that growth cost money: operating income rose only 8.3% against 12.5% revenue growth, and the operating margin narrowed from 38.9% to 37.4%. Management nonetheless raised full-year 2026 revenue guidance to $13.1–$13.2 billion from $12.95–$13.1 billion — a range that explicitly excludes the pending Crinetics deal. Vertex is paying up front to convert a one-drug company into a multi-franchise one, and in July it raised the stakes with a $10.0 billion cash offer for Crinetics Pharmaceuticals.
1. Consolidated Balance Sheet
1-1. Major asset lines
| Item | Dec 31, 2025 ($M) | Jun 30, 2026 ($M) | Change |
|---|---|---|---|
| Cash and cash equivalents | 5,084.8 | 6,143.5 | +20.8% |
| Marketable securities (current) | 1,523.3 | 1,708.9 | +12.2% |
| Accounts receivable, net | 2,052.8 | 2,134.3 | +4.0% |
| Inventories | 1,686.8 | 1,765.1 | +4.6% |
| Property and equipment, net | 1,520.3 | 1,665.0 | +9.5% |
| Goodwill | 1,088.0 | 1,088.0 | 0.0% |
| Other intangible assets, net | 424.2 | 412.8 | -2.7% |
| Long-term marketable securities | 5,712.3 | 5,789.1 | +1.3% |
| Total assets | 25,643.0 | 27,423.3 | +6.9% |
Source: Vertex Q2 2026 Form 10-Q, condensed consolidated balance sheets.
The most useful signal here is what did not grow. Revenue rose 10.2% in the first half, but receivables rose only 4.0% and inventories only 4.6% over the same six months. Sales are converting to cash rather than piling up as claims on customers or unsold product. Days sales outstanding — how long it takes to collect a bill — work out to roughly 58 days on second-quarter revenue (our calculation: quarter-end receivables divided by average daily Q2 revenue; the company does not disclose the metric).
Inventory mix is worth one line. Work-in-process is $1,253.9 million of the $1,765.1 million total, with finished goods at $278.2 million and raw materials at $233.0 million. That heavy WIP weighting is normal for a company manufacturing a cell therapy (CASGEVY) with long production cycles.
Total cash, cash equivalents and marketable securities reached $13,641.5 million, up from $12,320.4 million at year-end. Deferred tax assets stand at $3,010.9 million. The filing does not break down what sits inside that balance, so treat any single explanation with caution — but the company did expense $4.4 billion of in-process research and development on the 2024 Alpine Immune Sciences acquisition, and U.S. rules requiring R&D to be amortized for tax purposes both push in the same direction. Either way it is a real future cash-tax shield.
Debt maturity structure: as of June 30, 2026 Vertex carried no meaningful borrowings. Cash paid for interest in the first half was $6.3 million, against $6.2 million a year earlier. That changes after quarter-end — see Section 4. Operating lease assets of $1,662.9 million against long-term operating lease liabilities of $1,977.6 million reflect ASC 842 treatment of the company's Boston headquarters and manufacturing footprint.
1-2. Liability structure
Total liabilities of $7,175.4 million are almost entirely operating in nature: accrued expenses $3,179.0 million (up 7.0%, tracking the commercial ramp and gross-to-net rebate reserves), accounts payable $429.5 million (down 7.0%), and lease obligations. The current ratio improved to 3.19 from 2.90.
1-3. Capital structure
The equity account tells the buyback story cleanly. Additional paid-in capital fell 12.0% to $4,505.7 million, because share repurchases are charged there rather than to a separate treasury line. Retained earnings rose $2,131.2 million — exactly the first-half net income, confirming Vertex pays no dividend.
Accumulated other comprehensive income swung from negative $15.9 million to positive $48.5 million, a $64.4 million move. The components do not net the way a quick read suggests: $124.6 million of after-tax gains on foreign currency forward contracts were partly offset by $48.6 million of unrealized losses on available-for-sale debt securities and $11.6 million of negative foreign currency translation.
Shareholders' equity is $20,247.9 million, or 73.8% of total assets. Shares outstanding declined only 0.25% to 253.3 million, because buybacks were largely offset by stock-based compensation issuance.
2. Consolidated Statement of Income
2-1. Core earnings metrics
| Item | Q2 2025 ($M) | Q2 2026 ($M) | Change | 1H 2025 ($M) | 1H 2026 ($M) | Change |
|---|---|---|---|---|---|---|
| Total revenues | 2,964.7 | 3,333.9 | +12.5% | 5,734.9 | 6,320.8 | +10.2% |
| Operating income | 1,152.0 | 1,247.3 | +8.3% | 1,784.3 | 2,385.6 | +33.7% |
| Operating margin | 38.9% | 37.4% | -1.5%p | 31.1% | 37.7% | +6.6%p |
| Net income | 1,032.9 | 1,099.8 | +6.5% | 1,679.2 | 2,131.2 | +26.9% |
| Net margin | 34.8% | 33.0% | -1.8%p | 29.3% | 33.7% | +4.4%p |
| Diluted EPS ($) | 3.99 | 4.31 | +8.0% | 6.48 | 8.33 | +28.5% |
Source: Vertex Q2 2026 Form 10-Q, condensed consolidated statements of income.
Two adjustments are needed before these lines mean anything.
First, the top line understates product momentum. Q2 2025 total revenue included $20.7 million of "other revenues" that did not recur in 2026. On product revenue alone — $3,333.9 million against $2,944.0 million — growth was 13.2%, not 12.5%.
Second, the first-half comparison is distorted. The 1H 2025 base carries a $379.0 million intangible asset impairment charge, taken in the first quarter of 2025 when Vertex discontinued the VX-264 type 1 diabetes program acquired from Semma Therapeutics. It did not recur. Adding it back gives normalized 1H 2025 operating income of $2,163.3 million and a normalized margin of 37.7% — identical to this year's 37.7%. So the honest first-half growth rate is 10.3%, not 33.7%, and the margin was flat, not up 6.6 percentage points. The headline improvement is an accounting echo, not a business one.
Operating leverage — how much profit responds to each unit of sales — ran at 0.67 times in the quarter. Revenue grew 12.5%, operating income only 8.3%. Anything below 1.0 means costs are outrunning sales. For a company with 85% gross margins, that is a deliberate choice rather than a loss of control.
Investors should also note the GAAP/non-GAAP spread. Vertex reported non-GAAP EPS of $4.73, up 5% year over year, against GAAP diluted EPS of $4.31, up 8.0%. The consensus most headlines quote is the non-GAAP number; the analysis above is GAAP throughout, which is why the growth rates differ.
Three-year revenue CAGR through FY2025 was 10.4% ($8,930.7 million in 2022 to $12,001.3 million in 2025). The current pace is in line with that trend.
The effective tax rate rose to 21.0% from 19.5%, in line with the 21% U.S. federal statutory rate this quarter. Last year's lower rate reflected both excess tax benefits on stock-based compensation and tax credits, per the filing; neither recurred at the same scale this quarter. That difference explains why net income (+6.5%) grew slower than operating income (+8.3%).
2-2. Where the money went
| Cost line (Q2, $M) | 2025 | 2026 | Change | % of revenue 2026 |
|---|---|---|---|---|
| Cost of sales – products | 140.5 | 218.3 | +55.4% | 6.5% |
| Cost of sales – royalty | 267.0 | 270.9 | +1.5% | 8.1% |
| Research expenses | 209.3 | 207.3 | -1.0% | 6.2% |
| Development expenses | 769.1 | 786.5 | +2.3% | 23.6% |
| Selling and other commercial | 264.6 | 388.1 | +46.7% | 11.6% |
| General and administrative | 160.0 | 194.1 | +21.3% | 5.8% |
Source: Vertex Q2 2026 Form 10-Q, segment expense disclosure.
This table is the entire margin story. R&D — the largest cost block at $993.8 million combined — was essentially flat, falling from 33.0% of revenue to 29.8%. That produced 3.2 percentage points of margin relief. It was more than consumed by selling, general and administrative expense, which grew 37.1% and rose from 14.3% to 17.5% of revenue, and by cost of sales, which climbed from 13.8% to 14.7% of net product revenue on product mix.
Under U.S. GAAP all R&D is expensed immediately; it cannot be capitalized as it can under IFRS. Vertex's operating margin is therefore stated more conservatively than that of an IFRS-reporting peer, and the two are not directly comparable.
The read-through: Vertex has stopped increasing research spending and started spending on salesforces for CASGEVY and JOURNAVX. Selling costs are front-loaded and largely fixed once hired. If the new products scale, this reverses into positive leverage. If they stall, the cost stays.
3. Consolidated Statement of Cash Flows
| Item (six months, $M) | 2025 | 2026 | Change |
|---|---|---|---|
| Operating cash flow | 1,892.0 | 2,553.5 | +35.0% |
| Investing cash flow | (540.3) | (477.7) | — |
| Financing cash flow | (1,029.6) | (965.5) | — |
| Ending cash and restricted cash | 4,982.0 | 6,154.1 | +23.5% |
Source: Vertex Q2 2026 Form 10-Q, condensed consolidated statements of cash flows. The $6,154.1 million ending balance exceeds the $6,143.5 million of cash and cash equivalents on the balance sheet because the cash flow statement includes restricted cash.
Free cash flow — operating cash flow less capital spending — was $2,307.9 million, up 35.3% from $1,705.6 million. Capital expenditure of $245.6 million is 3.9% of first-half revenue, a maintenance-level figure for a specialty pharma company.
Quality of earnings is strong and improving. Operating cash flow was 1.20 times net income, up from 1.13 a year earlier. Anything at or above 1.0 means reported profit is backed by cash. Three things drive the gap. $336.6 million of stock-based compensation is a real expense that consumes no cash, equal to 5.3% of revenue. Working capital flipped from a $400.9 million drain last year to a $129.7 million source this year — a $530.6 million swing, led by prepaid expenses and other assets ($226.5 million, from a $104.5 million use to a $122.0 million source) and inventories ($190.3 million, from a $315.7 million use to a $125.4 million use). And cash taxes fell to $501.5 million from $697.7 million even as pre-tax income rose 31.4%.
Financing outflows are almost entirely returns of capital: $806.4 million of buybacks and $232.8 million of employee tax withholding, against $74.7 million of stock issuance proceeds. There was no new borrowing during the half.
4. Issues Investors Should Track
Guidance went up, but it does not include the deal. Vertex raised 2026 revenue guidance to $13.1–$13.2 billion from $12.95–$13.1 billion, with more than $500 million of that expected from non-CF products. The company said the range reflects no contribution from Crinetics and that it will update guidance after the transaction closes. Any model built on the current range is therefore a pre-deal model.
The ALYFTREK conversion is working, and it carries a legal tail. ALYFTREK is Vertex's next-generation CF therapy, designed to replace TRIKAFTA with once-daily dosing and — critically — a lower royalty burden. Management's position is that ALYFTREK carries a 4% third-party royalty under its Cystic Fibrosis Foundation agreement. On October 10, 2025, Royalty Pharma, which acquired the CFF's rights, initiated confidential arbitration alleging the rate is approximately 8%. Cumulative ALYFTREK revenue since launch is $1.8 billion, so the disputed 4-percentage-point gap is roughly $72 million to date, plus interest, damages and costs that Royalty Pharma is also seeking. No material loss contingency was accrued as of June 30, 2026. The exposure is not large today. It compounds with every quarter ALYFTREK grows, and ALYFTREK is growing at triple digits.
Diversification is real but still small. CASGEVY reached $76.4 million (+151% year over year, +78% sequentially) and JOURNAVX $49.6 million (+313% year over year, +71% sequentially). Together they are $126.0 million, or 3.8% of quarterly revenue. Cystic fibrosis still accounts for 96.2% of revenue, and TRIKAFTA/KAFTRIO alone for 74.9%. Vertex remains, financially, a cystic fibrosis company. The trajectory of the two new launches matters far more than their current contribution.
Access is the gating factor on the new launches. Vertex reported roughly 535,000 JOURNAVX prescriptions filled in the quarter and 900,000 in the half across hospital and retail settings, with approximately 260 million individuals now holding reimbursed access. Seniors covered by three of the four major Medicare Part D pharmacy benefit managers now have reimbursed access, and 23 states cover the drug through Medicaid. For CASGEVY, FDA approval extended to children aged two and older, making roughly 5,500 patients eligible for the first time, with German reimbursement (ages 12 and up) secured in May. ALYFTREK added four countries in the quarter, including Spain, bringing reimbursed markets to 25.
The Crinetics acquisition rewrites the balance sheet. On July 6, 2026 Vertex agreed to acquire Crinetics Pharmaceuticals for $85.00 per share in cash, a total equity value of approximately $10.0 billion, expected to close in the third quarter. Crinetics brings PALSONIFY (paltusotine), an approved once-daily oral therapy for acromegaly, and atumelnant in Phase 3 for congenital adrenal hyperplasia. On July 30, 2026, Vertex entered a $4.5 billion senior unsecured delayed-draw term loan A with Bank of America as administrative agent, replacing the 364-day bridge commitment signed alongside the merger agreement. The tranches mature at 364 days ($1.0 billion), two years ($1.0 billion), and three years ($2.5 billion), priced at SOFR plus 0.875%–1.625% depending on leverage. Nothing has been drawn yet. A company that paid $6.3 million of interest in the first half is about to become a leveraged borrower, and roughly $5.5 billion of its $13.6 billion cash pile is spoken for.
Pipeline catalysts are dated and near. The FDA accepted Vertex's biologics license application for accelerated approval of povetacicept in adults with IgA nephropathy and set a PDUFA target action date of November 30, 2026 — the single hardest date on the calendar. If approved, it becomes the first commercial product in Vertex's nephrology franchise. A parallel accelerated-approval submission is filed in Saudi Arabia, which has granted Breakthrough Designation. In primary membranous nephropathy, the Phase 2B portion of the OLYMPUS trial is complete and the Phase 3 portion is underway. Elsewhere: inaxaplin for APOL1-mediated kidney disease should finish enrollment in the AMPLITUDE pivotal trial in the second half of 2026, with interim data expected in early 2027; suzetrigine's Health Canada submission for acute pain is under review, with Phase 3 enrollment in diabetic peripheral neuropathy targeted for completion by year-end.
The Korea angle sits in the out-licensing table. Vertex does not sell povetacicept in Asia itself. In June 2025 it licensed Japan and South Korea rights to Ono Pharmaceutical, and in January 2025 licensed mainland China, Hong Kong, Macau, Taiwan and Singapore to Zai Lab. Ono runs the trials, filings and commercialization in Korea; Vertex keeps milestone payments and tiered royalties on net sales. For Korean investors, a November PDUFA win is therefore read through Ono, not through VRTX's own Korean revenue line.